{"changes":[],"country":"US","description":"T3D Therapeutics develops T3D-959, a metabolic disease-modifying drug for Alzheimer's and Huntington's disease. It serves patients with Alzheimer's and other neurodegenerative diseases tied to brain energy dysfunction. The first-in-class metabolic mechanism targets memory, motor function, and cognition simultaneously rather than amyloid plaques alone.","domain":"t3dtherapeutics.com","employees":null,"founded":2013,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":35.892377,"lng":-78.86589,"location":"Research Triangle Park, North Carolina, USA","name":"T3D Therapeutics, Inc.","rounds":[{"amountQuarantined":false,"amountUsd":2500000,"currency":"USD","date":"2023-08-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sbir","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"t3dtherapeutics-com","sources":[{"fact":"round","publisher":"sbir","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"t3dtherapeutics.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://t3dtherapeutics.com"},{"fact":"description","publisher":"t3dtherapeutics.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://t3dtherapeutics.com"}],"stage":null,"techStack":["WordPress 6.7.5","FitVids.JS 4.27.6","Sucuri","jQuery Migrate 3.4.1","jQuery Mobile","Easy Pie Chart","PHP","MySQL","jquery 3.7.1"],"totalRaisedUsd":2462840,"updatedAt":"2026-05-08"}